[Cost-effectiveness of quadrivalent vaccine against human papilloma virus in Argentina based on a dynamic transmission model]. / Costo-efectividad de la vacuna tetravalente contra VPH en Argentina, a partir de un modelo dinámico de transmisión.
Salud Publica Mex
; 57(6): 504-13, 2015.
Article
em Es
| MEDLINE
| ID: mdl-26679313
ABSTRACT
OBJECTIVE:
To assess the cost-effectiveness of the quadrivalent vaccine against human papillomavirus (HPV) in Argentina from the health system perspective. MATERIALS ANDMETHODS:
A dynamic transmission model was used to estimate the impact of the vaccine on the incidence of cervical cancer, warts, and other HPV related diseases; in quality adjusted life years (QALYs); and in healthcare costs.RESULTS:
Vaccination could reduce the risk of cervical cancer by 60% and by 67% the risk of genital warts. Compared to a non-vaccine scenario, the immunization strategy showed an incremental benefit of 0.00234 QALY per person at an incremental cost of US$2.36, resulting in an incremental cost-effectiveness ratio of US$1007.55 per QALY gained. Sensitivity analysis proved the robustness of these results.CONCLUSIONS:
Immunization with the quadrivalent vaccine was a cost-effective intervention in Argentina, and it was far below the threshold of one gross domestic product per capita (US$15 009) per QALY gained.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Condiloma Acuminado
/
Neoplasias do Colo do Útero
/
Vacinação
/
Infecções por Papillomavirus
/
Vacina Quadrivalente Recombinante contra HPV tipos 6, 11, 16, 18
/
Neoplasias dos Genitais Femininos
Tipo de estudo:
Health_economic_evaluation
Limite:
Child
/
Female
/
Humans
País/Região como assunto:
America do sul
/
Argentina
Idioma:
Es
Ano de publicação:
2015
Tipo de documento:
Article